<DOC>
	<DOCNO>NCT00602745</DOCNO>
	<brief_summary>The primary objective study determine whether S-1 increase overall survival compare 5-Fluorouracil ( 5-FU ) patient metastatic pancreatic cancer previously treat gemcitabine-based therapy . The secondary objective compare : progression free survival , overall response rate , clinical benefit improvement tumor relate symptom also assess overall safety pharmacokinetics S-1 .</brief_summary>
	<brief_title>S-1 Versus 5-FU Bolus Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Cytologically histologically confirm evidence adenocarcinoma exocrine pancreas Metastatic disease previously treat gemcitabinebased regimen Locally advance disease More one prior chemotherapyline advance pancreatic disease Prior treatment fluoropyrimidines advance pancreatic cancer Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; or= 2 Poor kidney , liver bone marrow function Any serious active disease comorbid condition , opinion principle investigator , interfere safety compliance study Unable swallow capsule Hypersensitivity history constituent study medication fluoropyrimidines Concurrent participation another clinical trial treatment anticancer therapy The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>pancreatic cancer</keyword>
</DOC>